Monte Rosa Therapeutics(US:GLUE)2026-03-17 11:04Financial Performance - Monte Rosa reported a net loss of $46.1 million for Q4 2025, compared to a net loss of $13.4 million in Q4 2024, and a net loss of $38.6 million for the full year 2025, down from $72.7 million in 2024[18]. - Total operating expenses for the year ended December 31, 2025, were $177.9 million, compared to $156.7 million in 2024, reflecting an increase in research and development costs[29]. - The net loss for the year ended December 31, 2025, was $38.6 million, an improvement from a net loss of $72.7 million in 2024[29]. Revenue and Collaboration - Collaboration revenue for Q4 2025 was $2.8 million, significantly lower than $60.6 million in Q4 2024, while total collaboration revenue for 2025 was $123.7 million, up from $75.6 million in 2024[15]. - Collaboration revenue for the year ended December 31, 2025, was $123.7 million, an increase from $75.6 million in 2024[29]. - The company has a collaboration agreement with Novartis for MRT-6160, with potential milestone payments up to $2.1 billion and shared profits from U.S. commercialization[14]. Expenses - Research and Development (R&D) expenses increased to $42.0 million in Q4 2025 from $38.9 million in Q4 2024, with total R&D expenses for 2025 reaching $141.5 million, compared to $121.6 million in 2024[16]. - General and Administrative (G&A) expenses rose to $10.5 million in Q4 2025 from $8.8 million in Q4 2024, with total G&A expenses for 2025 at $36.4 million, compared to $35.2 million in 2024[17]. Cash and Funding - As of December 31, 2025, the company's cash, cash equivalents, restricted cash, and marketable securities totaled $382.1 million, a decrease of $14.1 million from $396.2 million as of September 30, 2025[19]. - The company closed a public equity offering in January 2026, generating approximately $345.0 million in gross proceeds, with net proceeds expected to be around $323.8 million after expenses[20]. - The company anticipates that its cash and cash equivalents, along with proceeds from the 2026 offering, will be sufficient to fund operations and capital expenditures into 2029[21]. - Monte Rosa raised $345 million through an upsized public offering, strengthening its balance sheet to support operations into 2029[2]. Clinical Development - MRT-8102 demonstrated a 85% reduction in CRP levels after four weeks of administration in subjects with elevated CVD risk, with 94% of participants achieving CRP levels below 2 mg/L[4]. - The company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with Stage 3/4 chronic kidney disease in H2 2026, gout flare patients in Q4 2026/Q1 2027, and hidradenitis suppurativa patients in H1 2027[12]. - Anticipated readout of the GFORCE-1 study for MRT-8102 in subjects with elevated CVD risk is expected in H2 2026[13]. - The company plans to initiate the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC in Q3 2026[22]. - An IND application for a cyclin E1-directed MGD is expected to be submitted in 2026[22]. - MRT-2359 showed a 100% PSA response rate in mCRPC patients with AR mutations, with a 67% overall RECIST disease control rate across 15 evaluable patients[7]. Pipeline Development - The company has developed a leading pipeline of first-in-class and only-in-class molecular glue degraders (MGDs) across various therapeutic areas, with three programs currently in the clinic[23]. - The total assets as of December 31, 2025, were $448.7 million, compared to $438.7 million as of December 31, 2024[27].